重性抑郁障碍诊断、风险评估与治疗中科学议题的改进
该文回顾近二十年重性抑郁障碍生物学与治疗研究进展,指出诊断标准维度、临床预测因子效用、盲法试验及临床前模型等关键问题,并提出可能解决方案以避免研究误导。
要点
- 诊断标准或需纳入新维度以改进重性抑郁障碍诊断。
- 临床应答预测因子效用有限,传统盲法试验在重性抑郁障碍中应用受限。
- 临床前模型对新药开发的预测价值存疑,需审慎对待。
核心结论
- 重性抑郁障碍研究需解决诊断维度、预测因子、试验设计与临床前模型等关键问题,避免研究误导。
研究设计与样本
- 综述近二十年重性抑郁障碍生物学与治疗研究进展,讨论诊断与治疗开发中的科学议题。
主要发现
- 诊断标准可能需纳入新维度,临床应答预测因子效用有限,传统盲法试验应用减少,临床前模型预测价值不确定。
临床怎么用
- 临床应关注诊断维度拓展、预测因子局限性及试验设计变化对重性抑郁障碍诊疗的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the past two decades, research in the biology and treatment of major depression has led to advances in our understanding of the biology of the disorder and to the development of novel treatments. While progress has been made, a number of key issues have emerged regarding diagnosis of the disorder and how we develop and test new therapies. Among these are the potential need to include new dimensions in the diagnostic criteria, the limited utility of clinical predictors of response, the moving away from traditional blinded trials in major depression, and whether preclinical models tell us much about novel drug development. These issues need to be addressed to avoid the field's embarking on trails of research and treatment development that could actually mislead or misdirect our efforts to develop better diagnostic tools and more effective treatments. Possible solutions to these problems are proposed.
引用
- Schatzberg AF. Scientific Issues Relevant to Improving the Diagnosis, Risk Assessment, and Treatment of Major Depression. Am J Psychiatry. 2019. PMID: 31039643. doi:10.1176/appi.ajp.2019.19030273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。